France vs Netherlands: Access to anti-retroviral drugs, male
France
89.0%
in 2022
Netherlands
89.0%
in 2023
France rank
17th
Netherlands rank
17th
Access to anti-retroviral drugs, male over time
- France
- Netherlands
How they compare
France currently reports 89.0% against 89.0% in Netherlands, a difference of 0.0%.
The two have swapped places 2 times across 23 shared years of data; in 2000 it was France ahead.
France ranks 17th and Netherlands ranks 17th of 141 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | France | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 79.8% | 50.8% | 29.0% | France |
| 2010s | 86.9% | 76.8% | 10.1% | France |
| 2020s | 88.7% | 88.0% | 0.7% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, France or Netherlands?
- France, at 89.0% against 89.0% in Netherlands as of 2022.
- What is the difference in access to anti-retroviral drugs, male between France and Netherlands?
- 0.0%, with France ahead.
- How many years of comparable data are there for France and Netherlands?
- 23 years are reported by both, from 2000 to 2022.
- How do France and Netherlands rank globally for access to anti-retroviral drugs, male?
- France ranks 17th and Netherlands ranks 17th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.